Lung Cancer Treatment at Shanghai Pulmonary Hospital - A patient story
In April 2025, Shanghai Pulmonary Hospital welcomed a special patient, Ms. Dietrich from the United States. In 2024, doctors dia...
lung-cancer-treatment
On May 14, 2025, the Food and Drug Administration granted accelerated approval for telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-targeted antibody and microtubule inhibitor conjugate, for...
lung-cancer-treatment
On December 18, 2024, the Food and Drug Administration sanctioned ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or ...
lung-cancer-treatment
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou (FAHZU)
The first affiliated hospital of Zhejiang University is The First Affiliated Hospital, Zhejia...
lung-cancer-treatment
lung-cancer-treatment
Lung Cancer Surgery
Lung cancer is one of the most common and fatal cancers globally, and surgery is a major treatment for suitable patients. Surgical advancements have enhanced survival rates and mi...
lung-cancer-treatment
Lung Cancer Treatment
Lung cancer is one of the most common and life-threatening cancers globally, causing a large number of cancer deaths. Medical science has made significant progress in offering d...
lung-cancer-treatment
Non-Small Cell Lung Cancer (NSCLC) Surgery
Introduction
Non-small cell lung cancer (NSCLC) surgery is also one of the main treatment approaches for early-stage NSCLC-diagnosed patients...
lung-cancer-treatment